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PTEN  has been  heavily  studied  due  to its  role as  a  tumour  suppressor  and  as  a core  inhibitory  component
of  the phosphoinositide  3-kinase  (PI3K)  signalling  network.  It is  a broadly  expressed  phosphatase  which
displays  complexity  and  diversity  in both  its  functions  and  regulation  and  accordingly,  in the  labora-
tory  numerous  classes  of  functionally  distinct  mutations  have  been  generated.  Inherited  loss  of  function
mutations  in  the  PTEN  gene  were  originally  identiﬁed  in  sufferers  of  Cowden  disease,  but later  shown  to
associate  with  more  diverse  human  pathologies,  mostly  relating  to cell and tissue  overgrowth,  leading  to
the use  of the broader  term,  PTEN  Hamartoma  Tumour  Syndrome.  Recent  phenotypic  analysis  of  clinical
cohorts  of PTEN  mutation  carriers,  combined  with  laboratory  studies  of the  consequences  of these  muta-hosphatase
umour suppressor
utation
ancer
utism spectrum disorder
tions  implies  that  stable  catalytically  inactive  PTEN  mutants  may  lead  to the  most  severe  phenotypes,  and
conversely,  that  mutants  retaining  partial  function  associate  more  frequently  with  a  milder  phenotype,
with  autism  spectrum  disorder  often  being  diagnosed.  Future  work  will  be needed  to conﬁrm  and  to
reﬁne  these  genotype–phenotype  relationships  and  convert  this  developing  knowledge  into  improved
patient  management  and  potentially  treatment  with  emerging  drugs  which  target the  PI3K  pathway.
© 2016  The  Authors.  Published  by Elsevier  Ltd. This  is an open  access  article  under  the  CC BY  license
(http://creativecommons.org/licenses/by/4.0/).
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. Introduction were shown to be causative of Cowden disease, a phenotypi-In 1997, PTEN, was ﬁrst identiﬁed as a tumor suppressor gene
nd phosphatase mutated in multiple cancer types [1–3]. Soon
fter and based on gene localization, [4] germline PTEN mutations
∗ Corresponding author.
E-mail address: n.r.leslie@hw.ac.uk (N.R. Leslie).
ttp://dx.doi.org/10.1016/j.semcdb.2016.01.030
084-9521/© 2016 The Authors. Published by Elsevier Ltd. This is an open access article ucally complex cancer prone syndrome (OMIM: 158350) [5] and
its pediatric presentation, the Bannayan Riley Ruvalcaba Syndrome
(OMIM: 153480) [6]. The diversity of phenotypes now observed in
PTEN mutation carriers and the numerous organs and cell types
affected provide important evidence for the multiple actions of
the PI3K/PTEN signalling network in the regulation of many cel-
lular processes and sit well alongside many studies conducted in
cultured cells and animal models. Here we discuss how studies of
nder the CC BY license (http://creativecommons.org/licenses/by/4.0/).
 & Dev
p
t
m
m
t
g
a
s
p
e
t
m
p
p
d
b
o
a
ﬁ
[
h
p
i
s
y
P
[
i
t
p
i
f
T
n
t
w
s
k
e
p
i
s
m
p
2
m
2
[
a
e
i
a
c
t
i
i
t
w
(N.R. Leslie, M. Longy / Seminars in Cell
atient phenotypes have linked to our understanding of PTEN func-
ion at the molecular and cellular level and conversely whether this
ay  allow clinically useful prediction of the phenotype of PTEN
utation carriers.
The PI3K (class I phosphoinositide 3-kinase) signalling sys-
em is activated by diverse extracellular stimuli, including many
rowth factors, hormones including insulin, cytokines, chemokines
nd extracellular matrix components, which drive PI3K-dependent
ynthesis of phosphatidylinositol 3,4,5-trisphosphate (PIP3) in the
lasma membrane. In turn, increased PI3K activity and PIP3 lev-
ls promote the growth, proliferation and survival of many cell
ypes, as well as inﬂuencing cell metabolism, polarity and move-
ent, all through effects on a large and diverse set of PIP3-binding
roteins which include the AKT protein kinases [7]. PTEN is a lipid
hosphatase which directly opposes the function of the PI3Ks by
ephosphorylating PIP3. Accordingly, loss of PTEN function has
een shown experimentally to cause many disturbances in cell and
rganism physiology, commonly linked to increases in cell growth
nd proliferation [8–10] and clinically PTEN loss has been identi-
ed as a driver event in the development of many sporadic cancers
11,12]. Functions for PTEN independent from its action on PIP3
ave been proposed [13–16], including protein substrates for its
hosphatase activity [17–19]. The discovery of a PTEN mutation
n two Cowden disease families, PTEN G129E, and characterisation
howing that this mutant enzyme lacks lipid phosphatase activity,
et retains protein phosphatase activity was a key factor connecting
TEN lipid phosphatase activity with tumour suppressor function
20,21]. However, the signiﬁcance of these alternative functions
ncluding protein phosphatase activity is currently unclear and
he development of tumours both in these PTEN G129E carrying
atients and in PTEN G129E knockin mice indicates that PIP3-
ndependent functions of PTEN are not independently responsible
or its tumour suppressor functions in many organ systems [21–23].
he frequent loss of PTEN function and the activation of PI3K sig-
alling observed in many, probably most, tumours, has motivated
he development of a range of drugs targeting different points
ithin the PI3K signalling network, most notably the PI3Ks them-
elves, AKT and further downstream, the growth promoting TOR
inase, which is activated in part by AKT [24,25] (Fig. 1). These
fforts, involving most of the world’s major pharmaceutical com-
anies, have provided a range of drugs that relatively selectively
nhibit their targets in the clinic, but although there have been
ome notable successes [26,27], response rates for these drugs as
onotherapies against solid tumours have generally been disap-
ointing [28,29].
. The PTEN protein and the functional consequences of
utation
.1. The PTEN protein and its post-translational regulation
The PTEN gene encodes a 403 amino acid cytosolic protein
1–3,10], here termed PTEN, and also a recently described 576
mino acid protein which includes a 173 amino acid N-terminal
xtension. This longer protein is termed PTEN-L or PTEN-Long, and
ts function is currently unclear: it has been proposed to be secreted
nd potentially enter other cells or alternatively play a role in mito-
hondria [30–32]. Almost all functional studies of PTEN have used
he originally isolated 403 amino acid protein, although approaches
nterfering with the function of endogenous PTEN would generally
nterfere with both PTEN and PTEN-L proteins, making the func-
ional distinctions between the two currently hard to judge. Here
e will use ‘PTEN’ to refer to the 403 amino acid form.
Most of PTEN is made up of an N-terminal phosphatase domain
amino acids 7–185) and a tightly associated C2 domain (186–351)elopmental Biology 52 (2016) 30–38 31
which are required together for protein stability and catalysis
[33–35] and also both contain basic residues required for transient
membrane association and co-localisation with its phosphoinosi-
tide substrate [34,36–38] (Fig. 2). The less tightly structured
C-terminal tail of PTEN (352–403) appears to play regulatory roles,
containing two  clusters of phosphorylation sites. Four phospho-
rylatable residues in an acidic Ser-Asp-Thr-Thr-Asp-Ser cluster
at 380–385 appear to be phosphorylated by CK2 to relatively
high stoichiometry in analysed cells and tissues and a further
more N-terminal group, commonly displaying lower stoichiome-
try, encompass phosphorylation at Ser 370, perhaps also by CK2,
priming for phosphorylation at Thr 366 and perhaps Ser 362 by
GSK3 [39–42]. Phosphorylation at the 380–385 cluster is gener-
ally inhibitory to function. A series of consistent studies support
a model in which these phosphorylations lead to a closed confor-
mation through interaction of this phosphorylated acidic tail with
the basic Phosphatase-C2 core, greatly reduced interaction with
membranes and less biological activity and additionally increased
protein stability, apparently as a secondary consequence of reduced
membrane localisation [38,41–45]. Further sites of phosphoryla-
tion including Ser, Thr and Tyr residues have been identiﬁed, which
appear to be more cell-type selective in their phosphorylation, or at
least exhibit lower stoichiometry. Sites have also been identiﬁed at
which PTEN is oxidised and/or nitrosylated (C71, C124, C83), ubiq-
uitinated (including Lys13, Lys289), SUMOylated (Lys254, Lys266)
and acetylated (Lys 125, Lys128, Lys163, Lys402) although in most
of these examples of post-translational regulation, a clear picture is
yet to emerge of how these modiﬁcations of PTEN alter its function
and integrate into mechanisms of cellular regulation and this area
has been reviewed elsewhere [46–48].
2.2. Experimental analysis of the functional consequences of
PTEN mutations
One consequence of the requirement for both the PTEN phos-
phatase and C2 domains to form a minimal stable catalytic unit
is that any truncation or frameshift mutation leads to a complete
loss of stability and activity, other than mutations in the sequences
encoding the C-terminal tail (amino acids 352–403). In addition,
truncating mutations located within the ﬁrst eight exons lead to
mono allelic expression by nonsense mediated decay [49]. Con-
versely, any mutation in the C-terminal tail encoding by the ninth
exon, seems very unlikely to directly disrupt catalytic activity, and
more likely instead to inﬂuence protein stability and regulation.
In light of this, it is notable that although across many tumour
types there seems to be an underrepresentation of mutations in
sequences encoding the C-terminal tail, a signiﬁcant number of
mutations have been described there from sporadic gliomas (15
C-terminal mutations/734 total mutations in PTEN) and colorec-
tal cancers (10/387, omitting 11 mutations at aa 352 and 5 silent
mutations), but never in endometrial cancer (0/978) and very few
indeed in any germline cases (2/454) [50–53].
The PTEN protein fulﬁls a complex array of functions which have
been reviewed elsewhere [9–11]. Most notably, it regulates cell
growth and proliferation, in part via inﬂuences on the AKT group of
kinases [54] and also inﬂuences processes including chemotaxis
and epithelial cell and neuronal polarisation through mecha-
nisms involving localised PTEN activity and downstream mediators
[43,55–57]. PTEN displays unusually high protein sequence con-
servation. For example, the human and murine PTEN proteins
have only one conservative Ser-Thr amino acid difference, 99.75%
identity, whereas the genomic average human-murine ortholog
conservation is around 85% amino acid identity [58]. Recent data
from the 1000 Genomes project (www.1000genomes.org) gives us
a picture of variation within human populations, revealing very lit-
tle variation within PTEN. This database lists 54 single nucleotide
32 N.R. Leslie, M. Longy / Seminars in Cell & Developmental Biology 52 (2016) 30–38
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Fig. 1. Drug targets within the PI3K signalling network. (A) A model for the action of the class I phosphoinositide 3-kinase (PI3K) signalling network is shown. Activation
of  PI3K by diverse cell surface receptors, in particular receptor tyrosine kinases (RTKs), catalyses the phosphorylation of PtdIns(4,5)P2 to PtdIns(3,4,5)P3 (PIP3) using ATP
as  a phosphate donor. PTEN is a PI 3-phosphatase, which catalyses the reverse conversion of PIP3 to PtdIns(4,5)P2. Downstream effects are driven by PIP3 binding proteins,
including the Akt and Btk/Tec groups of kinases, activating Guanine Nucleotide Exchange Factors (GEFs) for the Rac and Arf families of GTPases and others. Direct effects
are  indicated by solid lines, indirect effects by dashed lines. Red circles indicate drug targets, in this case all kinases, for which inhibitors have progressed into clinical trials
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lmost all of these agents have been trialled extensively in patients with sporadic t
onducted speciﬁcally in Cowden/PHTS patients. Further details can be found in rec
ariants as candidate SNPs in the PTEN coding sequence of which
pproximately half appear to be included due to recorded asso-
iation with pathology. Only 3 of the candidate SNPs have been
dentiﬁed in more than 1 unrelated individual and current data
how none to have an apparent allele frequency in human popu-
ations above 0.001. Perhaps related to this, PTEN contains many
ifferent sites of post-translational modiﬁcation, many differenth inhibitor classes, examples and their stage of progression through clinical trials.
rs including the approved drugs. Only in a few cases (e.g. Sirolimus) are trials being
views [29,115–117,121,132].
amino acids contribute to its interactions with membrane lipids
and a large number of other proteins have been shown to interact
with different binding sites on PTEN [11,37,43,59].
Accordingly, numerous mutations designed in the laboratory
have been shown to disrupt speciﬁc regulatory features such as
protein–protein interactions and post-translational modiﬁcations,
without greatly impairing the catalytic activity of PTEN or its ability
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Fig. 2. The PTEN protein. The 48 kDa, 403 amino acid (aa) PTEN protein is shown. PTEN has an N-terminal protein tyrosine phosphatase (Phos) and more C-terminal C2
domain. The upper panel shows the 3D crystal structure of the minimal catalytic unit (7–353), lacking a less structured loop within the C2 domain (286–309) with the
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shosphatase domain on the left. The domain structure and post-translational mo
inding motif and the extreme C-terminal PDZ-binding sequence are shown in dar
larity only a small subset of probable sites is shown), Ubiquitin, (Ub), SUMO, oxida
o reduce cellular PIP3 levels and AKT activity, and the pheno-
ypes of these mutants are diverse and generally differ from those
f full null mutants [13,22,30,59–65]. The likelihood is therefore,
hat such functionally selective mutations arise in the human pop-
lation and will contribute similar phenotypic diversity. In silico
tructural analysis approaches have been developed with some
ower to predict the phenotypic consequences of mutations, based
n evolutionary conservation and other features, e.g. Mutation
ssessor [66]. By these methods, mutations disrupting core struc-
ural and catalytic features are likely to be correctly identiﬁed.
owever, while some classes of PTEN mutation have predictable
utcomes (e.g. truncations in all exons except the last), it remains
hat from only sequence information, predicting the functional con-
equences of many missense mutations is challenging.
There have been several attempts to investigate experimentally
he functional consequences of large numbers of clinically isolated
TEN missense mutations on function. Notably, Han et al. assayed
he phosphatase activity in vitro of 42 mutations identiﬁed in spo-
adic tumours or PHTS, ﬁnding 31 lacked all detectable catalytic
ctivity, 7 had only partial catalytic activity and 4 appeared fully
ctive [67]. Later, Rodriguez-Escudero et al. used an in vivo yeast
ssay to study the cellular activity of 68 disease associated PTEN
utants, ﬁnding rather more mutants displayed activity in this
etting, possibly due to greater protein stability in the cellular envi-
onment [68]. Almost 50% of the mutants in this study showed some
etectable activity, with 16 appearing similar to WT PTEN. These
uthors also identiﬁed important associations with speciﬁc pheno-
ypes which are discussed more below [68]. This key ﬁnding that
ome mutant enzymes retaining substantial cellular activity are
ssociated with sporadic and familial tumour formation is in line
ith the apparent dose-dependency of PTEN’s actions as a tumour
uppressor [69] and the known diversity of tumour related pro-
esses controlled by PI3K/PTEN with very different activity/output
ose relationships.
. PTEN Hamartoma Tumour Syndrome and the phenotype
f PTEN mutation carriers.1. Human germline PTEN mutation
Soon after the identiﬁcation of PTEN as a tumour suppres-
or, heterozygous mutations in the PTEN gene were identiﬁedions are shown in the lower panel. The positions of the N-terminal PtdIns(4,5)P2
ades of purple. Post-translational sites of modiﬁcation by phosphorylation (P—for
Ox) and acetylation (Ac) are indicated.
in patients suffering from the familial multi-system cancer
syndromes, Cowden disease and its pediatric presentation,
Bannayan–Riley–Ruvalcaba syndrome [5,70]. Later, the discovery
of inherited PTEN mutations associated with clinical manifesta-
tions as Lhermitte Duclos syndrome (or cerebellum dysplastic
hamartoma) [71] juvenile polyposis of infancy [72], segmental
overgrowth [73] or autism spectrum disorder with macrocephaly
[74,75] highlighted the complex relationship between genetic
changes which impair the functions of the PTEN protein and patient
phenotype. More recently, the umbrella term PTEN Hamartoma
Tumour Syndrome (PHTS) has been used to encompass the range of
symptoms identiﬁed in PTEN mutation carriers and broader diag-
nostic criteria have been proposed [76,77].
Several groups have studied the phenotypes of large cohorts
of PTEN mutation carriers, revealing the high lifetime cancer risk
in these patients and also the diversity of their other symp-
toms [78–80]. These studies indicate a lifetime cancer risk of over
80%, higher in women than men, with the highest risks being
female breast cancer (>75%), thyroid, kidney and endometrial can-
cers [78–80]. The most common features of these patients are
macrocephaly, gastrointestinal polyps with various histological
patterns and dermatological lesions including trichilemmoma and
oral papillomatosis which are each found in around 90% of these
PTEN mutation carriers [78,79]. Notably, while polyps and derma-
tological features are common in PTEN-mutation negative cases of
Cowden syndrome, rates of macrocephaly are much lower in these
cases (<40%) and it may  represent a usable distinguishing charac-
teristic to identify PTEN mutation carriers [81]. Many other features
are identiﬁed in these patients, mainly: complex benign mastopa-
thy, and multi-nodular thyroid lesions, of various intensity but also,
lipomas, invasive angiolipomas, ovarian cysts and uterine ﬁbroids
to cite the more frequently observed [78,79,82]. Because these clin-
ical manifestations are inconsistent from one patient to another
and, taken alone are common in patients without Cowden disease,
several teams have deﬁned phenotypically based scores predicting
of PTEN mutation [77,82,83]. It should be noted however that these
studies have understandably relied upon patient groups selected
for PTEN sequencing after diagnosis with previously deﬁned symp-
toms of PHTS and might therefore under-represent phenotypes
caused by speciﬁc functionally distinct mutation classes. The possi-
bility that some PTEN mutation carriers, perhaps with a functionally
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istinct class of PTEN mutation, display phenotypes reliably distin-
uishable from PHTS has been investigated particularly in the case
f individuals with ASD, as there are several reports of PTEN muta-
ions being identiﬁed in individuals with ASD and macrocephaly
ithout diagnosed additional characteristics of PHTS [74,84–87]
nd in a small number of individuals with sporadic ASD [88]. This
henotypic variability is also highlighted by other studies in which
atients presenting with individual PHTS phenotypes [89,90] or
alignancy without a prior PHTS diagnosis [62,91] are shown to
arry germline PTEN mutations yet fail to fulﬁl diagnostic criteria
or PHTS.
.2. Somatic mosaicism
Homogenous germline PTEN mutation are mainly found in Cow-
en disease but recently some cases with a somatic mosaicism of
TEN heterozygous mutation have been reported without major
henotype speciﬁcities [92]. More intriguing was the description
f a type 2 mosaicism of PTEN combining two loss of function
TEN mutations: the ﬁrst one in homogeneous state and the sec-
nd one, involving the second allele in a mosaic state [93]. The
ssociated phenotype henceforth named type 2 segmental Cow-
en disease [94] or SOLAMEN syndrome [73] was initially confused
ith the Proteus syndrome. Interestingly, Proteus syndrome itself
as subsequently linked to a mosaic gain of function mutation of
he AKT1 gene [95] encoding the PTEN regulated protein kinase,
KT1 (Table 1). Moreover, several overgrowth syndromes includ-
ng macrodactyly, CLOVE syndrome, megalencephaly-capillary
alformation or ﬁbroadipose hyperplasia have been related to
eterozygous gain of function PIK3CA mutation in a mosaic state
96]. These various segmental overgrowth syndromes show impor-
ant phenotypic overlaps probably because activating mutation of
IK3CA or AKT1 and biallelic loss of function mutation of PTEN have
imilar functional consequences on the PI3K–AKT–TOR signalling
etwork. These observations argue that the main phenotypic con-
equences of PTEN mutations are related to its role in the PIK3–AKT
athway, at least for the cells able to support constitutive activation
f this pathway.
. Phenotypic variability in human PTEN mutation carriers
nd genotype–phenotype relationships
.1. Clinical studies
As discussed in Section 2, individual mutations would be
xpected to have different effects on PTEN function and this has
een conﬁrmed in many studies [37,60,61,63,67,68,102]. How-
ver, sufﬁcient understanding of the PTEN protein relating to
ommon mutations inherited in the human population has taken
ime to develop, and reliable genotype–phenotype relationships
hich might help in patient management have not been estab-
ished. One difﬁculty in achieving this aim is that the phenotype of
TEN mutation carriers is strongly affected by other factors, includ-
ng genetic background and environmental factors. For example,
ndividual mutations have been found to lead to very different phe-
otypes in different individuals [78] even within the same family
103,104]. Such variability of the intra familial expression can be
bserved for the autism spectrum manifestations which involve
requently only one or a few members of a family, the others muta-
ion carriers showing a more classical phenotype. Interestingly, the
nly correlation that can be drawn from the molecular diagno-
is of the disease relates to the patients showing the association
acrocephaly–autism, in which a predominance of missense muta-
ion is detected. For example in a group of ten mutations found
or the clinical indication macrocephaly–autism, eight are missense
utation (M Longy, unpublished) while in other indications the fre-elopmental Biology 52 (2016) 30–38
quency of missense mutation is usually about 30% of the detected
mutations.
4.2. Modelling human disease in Pten mutant mice
Studies in mice genetically modiﬁed at the Pten locus have been
used to probe genotype phenotype relationships. Several studies
have generated whole animal and tissue-speciﬁc mouse lines car-
rying mutant Pten deletion alleles which remove all detectable
expression of the PTEN protein, leading to a range of tumours
with some overlap with those observed in PHTS [9,105,106] and
additional phenotypes including behavioural changes similar to
ASD [107]. The full spectrum of phenotypes observed in these
mice and their overlap with human subjects has been reviewed
elsewhere [8,9,76,108]. Comparison of two apparent ‘null’ alleles
indicates that differences in the phenotypes observed in different
mouse colonies, and by extension, probably by different research
groups, are caused by different genetic backgrounds [109]. Accord-
ingly, rigourous analysis of mice expressing unstable mutant PTEN
proteins also reveals phenotypes very similar to the null setting
[23,110].
In contrast, studies of knockin mice expressing characterised
stable mutant PTEN proteins which lack lipid phosphatase activ-
ity has led to very different conclusions [22,23]. Heterozygous
mice expressing both normal PTEN and also either PTEN C124S,
which lacks all detectable phosphatase activity, or PTEN G129E,
which selectively lacks activity against lipid substrates, have a sig-
niﬁcantly higher tumour burden than similar mice carrying one
wild-type allele along with one full null allele which expresses no
protein. This difference seemed particularly clear in the aggressive-
ness of observed breast tumours [22,23]. This provides evidence
for a dominant negative mechanism by which stable inactive pro-
tein disturbs the function of co-expressed wild-type protein and
perhaps aggravates normal cellular behaviour independently; a
paradigm that has been established with other tumour suppres-
sors including p53 [111]. The implications for human patients are
that those expressing stable yet inactive PTEN proteins may  have
a worse prognosis than those whose mutations simply cause a loss
of normal PTEN.
This hypothesis that inactive stable PTEN mutants aggravate
phenotype ﬁts with further laboratory studies of PTEN mutant func-
tion. Recent studies of small numbers of PTEN mutations identiﬁed
in patients with severe cases of PHTS showed that the encoded
mutant proteins lacked all detectable activity in cell based assays,
even when over-expressed [112]. This was in notable contrast to
mutant proteins identiﬁed in patients with ASD and macrocephaly
lacking other symptoms of PHTS, which, although most were unsta-
ble, all displayed normal activity in their ability to control P-AKT if
they were ever-expressed and those tested retained efﬁcacy in the
regulation of soma size in hippocampal neurons [112]. This lat-
ter ﬁnding supports the earlier conclusion of Rodriguez-Escudero
et al., who found ASD associated mutations were more likely to have
higher activity in a yeast based PTEN activity assay than mutants
associated with PHTS [68]. Finally, studies of ASD associated PTEN
alleles in cortical neurons showed an inability to rescue the selec-
tive loss of somatostatin positive interneurons caused by PTEN loss
and supported the conclusion that these alleles retain partial activ-
ity [113].
Together these studies support the important hypothesis that
PTEN mutations which lead to a partial loss of function of the
encoded protein are less likely to cause the more severe develop-
mental features associated with PHTS and are more likely to be
diagnosed in individuals with ASD and macrocephaly. These data
also support the converse conclusion that PTEN mutations which
cause the accumulation of stable inactive PTEN protein are more
likely to lead to severe developmental symptoms and malignancy
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Table  1
Human genetic diseases with symptoms related to PHTS.
Syndrome Gene(s) Comments References
PHTS PTEN See text
Juvenile  polyposis syndrome SMAD4, BMPR1A [97]
Proteus syndrome AKT1 Mosaic/somatic [95]
PIK3CA-related overgrowth spectrum (PROS) PIK3CA, AKT3 Mosaic/somatic [90,96,98,99]
Tuberous sclerosis TSC1, TSC2 [100,101]
Peutz-Jeghers syndrome LKB1/STK11 [97]
WILD TYPE PARTIALACTIVITY
STABLE 
INACTIVENO PROTEIN
HEALTHY MILD esp
ASD
INTERMEDIATE SEVERE
PTEN
PROTEIN
PHENOTYPE
Fig. 3. A hypothesis linking PTEN mutations with phenotype. The PTEN mutant protein phenotype is shown above, with partial activity representing either an unstable active
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rnzyme  (feint enzyme cartoon) or a stable enzyme with reduced activity (partially 
losed  active site. Mutations leading to partially active PTEN protein have been phe
een  linked to more severe PHTS phenotypes.
Fig. 3). This illustrates the difﬁculty of phenotype prediction, as
oth partially functional proteins and stable inactive proteins are
ost likely to be encoded by missense mutations with only lim-
ted grounds for predicting the consequences of each mutation on
rotein function (see Section—2.2). In this regard, building up and
ollating the body of data covering mutations with recognised con-
equences would be of great beneﬁt, as the robust experimental
etermination of PTEN activities and stability in appropriate assays
urrently remains a signiﬁcant task even in a specialist labora-
ory. It is worth noting therefore that genuine null alleles, which
isrupt the accumulation of PTEN, appear to have intermediate
everity [22,23,68,112,113] and regardless, the clear inﬂuence of
ther factors on phenotype makes patient management challeng-
ng [77,114].
. Therapeutic implications
The management of PHTS sufferers and other PTEN mutation
arriers is complex and has been reviewed elsewhere [114] gener-
lly involving surveillance, screening for malignancies and surgery.
owever, as previously mentioned, the implication of PTEN in
he negative control of the PI3K–AKT pathway led the pharma-
eutical industry to design many new inhibitors of this signalling
etwork that provide the promise of well-tolerated targeted ther-
pies (Fig. 1). Such therapies targeting the PI3K–TOR signalling
etwork and receptors that activate it have been extensively
eviewed as have the prospects for their application to Cowden
nd other related syndromes [25,115–117]. The pharmacological
gent rapamycin, known as an inhibitor of mTOR was previously
sed in preclinical studies on Pten+/− mice showing a cytostatic
ffect on endometrium hyperplasia and adrenal medullary neo-
lasia [118] and both chemoprevention and improved survival as
ell as regression of multiple lesions in an epithelial speciﬁc PTEN
eletion model of Cowden disease [119]. The same agent showed
 clinically improvement and a reduction of soft tissue mass in a
oung patient with SOLAMEN and invasive angiolipoma [120]. Cur-
ently, the results of clinical trials with TORC1 and PI3K inhibitors active site). A stable inactive enzyme is represented by an enzyme cartoon with a
ically linked to autism spectrum disorder (ASD) and fully inactive mutations have
in PTEN germline mutation carriers are yet pending (for review:
[121]). It should be noted that many other prognostic and pre-
dictive biomarkers are being developed to inform PI3K-pathway
targeted cancer therapies, some of which could be considered
alongside PTEN genotype in planning the treatment of PHTS suffer-
ers. However the signiﬁcance of these markers is currently unclear
[122,123].
A further ﬁnding that has motivated therapeutic testing is
the apparent reliance of PTEN null tumours on PI3K signalling
speciﬁcally activated through its PIK3CB-encoded p110 cat-
alytic isoform, observed in the prostate and other tumour types
[124–126]. However, this connection is not consistent for all
tumour types [127,128]. This point also highlights the challenges
of targeting a signalling network with multiple mechanisms to
modulate signal sensitivity via feedback and crosstalk, particularly
induced by PTEN loss [129,130]. Selective inhibition of p110 in
PTEN null tumours has been shown to lead in many cases to feed-
back activation of p110 (PIK3CA) dependent signalling and drug
resistance, diversifying the PI3K isoforms upon which these tumors
rely [128,131].
6. Concluding remarks
Understanding is beginning to develop of genotype–phenotype
relationships in PTEN mutation carriers with the potential to gen-
erate insight that is reliable and has utility in terms of prognosis
and therapeutic selection. However, the emergence of this appli-
cation would seem to require progress on several fronts. We  still
understand little about the downstream mechanisms driving PTEN
mutant pathology other than the AKT–TOR axis. Many other down-
stream PIP3-binding proteins and linked PI3K-responsive signalling
mechanism have been identiﬁed, yet their signiﬁcance in PTEN-
and PI3K-driven pathology is unknown and the same is true of the
many PI3K-independent processes which have been proposed to be
targets of PTEN regulation. Since it seems unlikely that PTEN itself
can be re-activated therapeutically, most treatments aim to inhibit
opposing signal activators and without improved knowledge of the
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mportance of these targets, it is hard to judge the likelihood of
uccess and, as has occurred recently in most cases, interpret poor
esults in clinical trials.
Other areas requiring research progress include the develop-
ent of large maintained and accessible datasets recording PTEN
arrier phenotype and the experimentally determined functional
onsequences of PTEN mutations, the latter feature also potentially
upported by simpler, more cost effective and reliable technolo-
ies to functionally characterise novel PTEN mutations at discovery.
ltimately, this protein-speciﬁc data should also provide a frame-
ork supporting greatly improved ways to predict PTEN mutation
everity beyond existing algorithms applicable to all proteins. In
he long term, and in advance of most genetic diseases, the large
ody of research providing solid understanding of PTEN function
nd mutation carriers, allied with the availability of several classes
f drugs targeting components of the PI3K–PTEN pathway should
ean that genuinely personalised medicine may  well be possible.
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